1
|
Graier T, Weger W, Jonak C, Sator P, Zikeli C, Prillinger K, Sassmann C, Gruber B, Saxinger W, Ratzinger G, Painsi C, Mlynek A, Häring N, Sadoghi B, Trattner H, Müllegger R, Quehenberger F, Salmhofer W, Wolf P. Author Correction: Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA). Sci Rep 2024; 14:7144. [PMID: 38532006 DOI: 10.1038/s41598-024-57807-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/28/2024] Open
Affiliation(s)
- T Graier
- Department of Dermatology and Venereology, Medical University of Graz, Auenbruggerplatz 8, 8036, Graz, Austria
| | - W Weger
- Department of Dermatology and Venereology, Medical University of Graz, Auenbruggerplatz 8, 8036, Graz, Austria
| | - C Jonak
- Medical University of Vienna, Vienna, Austria
| | - P Sator
- Clinic Hietzing, Vienna, Austria
| | - C Zikeli
- State Hospital Wiener Neustadt, Wiener Neustadt, Austria
| | - K Prillinger
- University Hospital of St. Poelten, Karl Landsteiner University of Health Sciences, Krems, Austria
| | - C Sassmann
- State Hospital Wiener Neustadt, Wiener Neustadt, Austria
| | - B Gruber
- Hospital of Wels-Grieskirchen, Wels, Austria
| | - W Saxinger
- Hospital of Wels-Grieskirchen, Wels, Austria
| | - G Ratzinger
- Medical University of Innsbruck, Innsbruck, Austria
| | - C Painsi
- State Hospital Klagenfurt, Klagenfurt, Austria
| | - A Mlynek
- Hospital of Elisabethinen, Linz, Austria
| | - N Häring
- Federal Academic Teaching Hospital, Feldkirch, Austria
| | - B Sadoghi
- Department of Dermatology and Venereology, Medical University of Graz, Auenbruggerplatz 8, 8036, Graz, Austria
| | - H Trattner
- Medical University of Vienna, Vienna, Austria
| | - R Müllegger
- State Hospital Wiener Neustadt, Wiener Neustadt, Austria
| | - F Quehenberger
- Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria
| | - W Salmhofer
- Department of Dermatology and Venereology, Medical University of Graz, Auenbruggerplatz 8, 8036, Graz, Austria
| | - Peter Wolf
- Department of Dermatology and Venereology, Medical University of Graz, Auenbruggerplatz 8, 8036, Graz, Austria.
| |
Collapse
|
2
|
Golob-Schwarzl N, Pilic J, Benezeder T, Bordag N, Painsi C, Wolf P. Eukaryotic Initiation Factor 4E (eIF4E) as a Target of Anti-Psoriatic Treatment. J Invest Dermatol 2024; 144:500-508.e3. [PMID: 37865179 DOI: 10.1016/j.jid.2022.12.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2022] [Revised: 12/13/2022] [Accepted: 12/15/2022] [Indexed: 10/23/2023]
Abstract
Eukaryotic initiation factor 4E (eIF4E) has been known to play a critical role in the regulation of gene expression and essential cellular processes, such as proliferation, apoptosis and differentiation. In this study, we explored its role in the pathophysiology of psoriasis. The inhibition of eIF4E by small interfering RNA or briciclib, an eIF4E small molecule inhibitor, downregulated the expression of eIF4E itself and its two complex partners eIF4A and G, as well as other eIFs (eg, eIF1A, eIF2α, eIF3A, eIF3B, eIF5, and eIF6). This inhibition also abolished psoriatic inflammation in both the imiquimod and TGFß mouse model, as well as in a human 3 dimensional-psoriasis tissue model. Downregulation of eIF4E and the other eIFs by application of briciclib (particularly when given topically) was linked to the normalization of cellular proliferation, epidermal hyperplasia, levels of proinflammatory cytokines (eg, TNFα, IL-1b, IL-17, and IL-22), and keratinocyte differentiation markers (eg, KRT16 and FLG). These results demonstrate translational imbalance and underline the crucial role played by eIF4E and other eIFs in the pathophysiology of psoriasis. This work opens up avenues for the development of novel topical antipsoriatic treatment strategies by targeting eIF4E.
Collapse
Affiliation(s)
| | - Johannes Pilic
- Department of Dermatology and Venereology, Medical University of Graz, Austria
| | - Theresa Benezeder
- Department of Dermatology and Venereology, Medical University of Graz, Austria
| | - Natalie Bordag
- Department of Dermatology and Venereology, Medical University of Graz, Austria
| | - Clemens Painsi
- Department of Dermatology and Venereology, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Austria
| | - Peter Wolf
- Department of Dermatology and Venereology, Medical University of Graz, Austria; BioTechMed Graz, Graz, Austria.
| |
Collapse
|
3
|
Benezeder T, Bordag N, Woltsche J, Teufelberger A, Perchthaler I, Weger W, Salmhofer W, Gruber-Wackernagel A, Painsi C, Zhan Q, El-Heliebi A, Babina M, Clark R, Wolf P. Mast cells express IL17A, IL17F and RORC, are activated and persist with IL-17 production in resolved skin of patients with chronic plaque-type psoriasis. Res Sq 2024:rs.3.rs-3958361. [PMID: 38410434 PMCID: PMC10896398 DOI: 10.21203/rs.3.rs-3958361/v1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/28/2024]
Abstract
Little is known about IL-17 expression in psoriasis and the actual cellular source of IL-17 remains incompletely defined. We show that high numbers of IL-17 + mast cells persisted in resolved lesions after treatment (anti-IL-17A, anti-IL-23, UVB or topical dithranol) and correlated inversely with the time span in remission. IL-17 + mast cells were found in T cell-rich areas and often close to resident memory T cells (Trm) in active psoriasis and resolved lesional skin. Digital cytometry by deconvolution of RNA-seq data showed that activated mast cells were increased in psoriatic skin, while resting mast cells were almost absent and both returned to normal levels after treatment. When primary human skin mast cells were stimulated with T cell cytokines (TNFα, IL-22 and IFNγ), they responded by releasing more IL-17A, as measured by ELISA. In situ mRNA detection using padlock probes specific for transcript variants of IL17A, IL17F, and RORC (encoding the Th17 transcription factor RORγt) revealed positive mRNA signals for IL17A, IL17F, and RORCin tryptase + cells, demonstrating that mast cells have the transcriptional machinery to actively produce IL-17. Mast cells thus belong to the center of the IL-23/IL-17 axis and high numbers of IL-17 + mast cells predict an earlier disease recurrence.
Collapse
Affiliation(s)
- Theresa Benezeder
- Department of Dermatology and Venereology, Medical University of Graz
| | - Natalie Bordag
- Department of Dermatology and Venereology, Medical University of Graz
| | - Johannes Woltsche
- Department of Dermatology and Venereology, Medical University of Graz
| | | | | | - Wolfgang Weger
- Department of Dermatology and Venereology, Medical University of Graz
| | | | | | | | - Qian Zhan
- Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School
| | - Amin El-Heliebi
- Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz
| | - Magda Babina
- Institute of Allergology, Charite-Universitatsmedizin Berlin
| | | | - Peter Wolf
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| |
Collapse
|
4
|
Graier T, Salmhofer W, Jonak C, Weger W, Zikeli C, Gruber B, Sator P, Prillinger K, Mlynek A, Schütz-Bergmayr M, Richter L, Ratzinger G, Sassmann C, Painsi C, Häring N, Wippel-Slupetzky K, Skvara H, Trattner H, Inzinger M, Bangert C, Ellersdorfer C, Falkensteiner K, Sadoghi B, Gruber-Wackernagel A, Hofer A, Legat F, Lange-Asschenfeldt B, Schmuth M, Vujic I, Hötzenecker W, Saxinger W, Müllegger R, Quehenberger F, Wolf P. Entwicklung der Patientencharakteristika und der Wirksamkeit der Biologika-Therapie bei Patienten des Österreichischen Psoriasis-Registers von 2004 bis 2022. J Dtsch Dermatol Ges 2023; 21:1513-1523. [PMID: 38082521 DOI: 10.1111/ddg.15213_g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2023] [Accepted: 07/21/2023] [Indexed: 12/18/2023]
Abstract
ZusammenfassungHintergrund und ZieleIn dieser Studie wurde untersucht, inwieweit die Einführung wirksamerer Medikamente in jüngster Zeit zu einer Verbesserung der Behandlungsergebnisse von Psoriasis‐Patienten im klinischen Alltag geführt hat.Patienten und MethodikEs wurden Patientencharakteristika und die Wirksamkeit der Therapie im ersten Behandlungsjahr bei Biologika‐naiven Patienten von 2004 bis heute analysiert, unabhängig von Therapiewechseln.ErgebnisseDie Daten von 2729 Patienten eigneten sich für die Analyse. Der Anteil der weiblichen Patienten stieg über die Jahre signifikant von 29,9% auf 36,2% (p < 0,028), während der Anteil der Patienten mit einer Psoriasis‐Arthritis von 36,6% auf 30,0% sank (p < 0,001). Außerdem nahm die Dauer der Psoriasis‐Erkrankung und der PASI‐Wert zu Beginn der Behandlung in Verlauf der Zeit signifikant ab. Die „letzte Beobachtung übernommen“ (LOCF)‐Analyse zeigte, dass das PASI‐90‐Ansprechen drei Monate nach Therapiebeginn von 18,9% auf 44,6% und 12 Monate nach Therapiebeginn von 32,9% auf 66,8% anstieg. Ebenso stiegen die PASI<3 Befunde von 33,2% auf 66,0% 3 Monate und von 41,9% auf 78,9% 12 Monate nach Behandlungsbeginn.SchlussfolgerungenDie kontinuierliche Einführung wirksamerer Biologika hat zu einer deutlichen Verbesserung des klinischen Ansprechens und der Patientenversorgung geführt. Dennoch erreicht auch heute noch, je nach gewähltem Endpunkt, jeder dritte bis fünfte Patient kein vollständig zufriedenstellendes Behandlungsergebnis (d.h. PASI 90 oder PASI ≤ 3).
Collapse
Affiliation(s)
- Thomas Graier
- Abteilung für Dermatologie und Venerologie, Medizinische Universität Graz, Graz, Österreich
| | - Wolfgang Salmhofer
- Abteilung für Dermatologie und Venerologie, Medizinische Universität Graz, Graz, Österreich
| | - Constanze Jonak
- Abteilung für Dermatologie, Medizinische Universität Wien, Wien, Österreich
| | - Wolfgang Weger
- Abteilung für Dermatologie und Venerologie, Medizinische Universität Graz, Graz, Österreich
| | - Claudia Zikeli
- Abteilung für Dermatologie und Venerologie, Landesklinikum Wiener Neustadt, Wiener Neustadt, Österreich
| | - Barbara Gruber
- Abteilung für Dermatologie und Venerologie, Krankenhaus Wels-Grieskirchen, Wels-Grieskirchen, Österreich
| | - Paul Sator
- Abteilung für Dermatologie, Klinik Hietzing, Wien, Österreich
| | - Knut Prillinger
- Abteilung für Dermatologie und Venerologie, Karl-Landsteiner-Universität, St. Pölten, Österreich
| | - Alexander Mlynek
- Abteilung für Dermatologie, Krankenhaus der Elisabethinen Linz, Linz, Österreich
| | - Martina Schütz-Bergmayr
- Abteilung für Dermatologie und Venerologie, Johannes-Kepler-Universität Linz, Linz, Österreich
| | - Leo Richter
- Abteilung für Dermatologie und Venerologie, Krankenhaus der Stadt Wien Rudolfstiftung, Wien, Österreich
| | - Gudrun Ratzinger
- Abteilung für Dermatologie, Venerologie und Allergologie, Medizinische Universität Innsbruck, Innsbruck, Österreich
| | - Christoph Sassmann
- Abteilung für Dermatologie und Venerologie, Landesklinikum Wiener Neustadt, Wiener Neustadt, Österreich
| | - Clemens Painsi
- Abteilung für Dermatologie und Venerologie, Landeskrankenhaus Klagenfurt, Klagenfurt, Österreich
| | - Nina Häring
- Abteilung für Dermatologie und Venerologie, Akademisches Lehrkrankgenhaus Feldkirch, Feldkirch, Österreich
| | | | - Hans Skvara
- Abteilung für Dermatologie und Venerologie, Landesklinikum Wiener Neustadt, Wiener Neustadt, Österreich
| | - Hannes Trattner
- Abteilung für Dermatologie, Medizinische Universität Wien, Wien, Österreich
| | - Martin Inzinger
- Abteilung für Dermatologie und Venerologie, Medizinische Universität Graz, Graz, Österreich
| | - Christina Bangert
- Abteilung für Dermatologie, Medizinische Universität Wien, Wien, Österreich
| | - Christina Ellersdorfer
- Abteilung für Dermatologie und Venerologie, Krankenhaus der Stadt Wien Rudolfstiftung, Wien, Österreich
| | | | - Birgit Sadoghi
- Abteilung für Dermatologie und Venerologie, Medizinische Universität Graz, Graz, Österreich
| | | | - Angelika Hofer
- Abteilung für Dermatologie und Venerologie, Medizinische Universität Graz, Graz, Österreich
| | - Franz Legat
- Abteilung für Dermatologie und Venerologie, Medizinische Universität Graz, Graz, Österreich
| | | | - Matthias Schmuth
- Abteilung für Dermatologie, Venerologie und Allergologie, Medizinische Universität Innsbruck, Innsbruck, Österreich
| | - Igor Vujic
- Abteilung für Dermatologie und Venerologie, Krankenhaus der Stadt Wien Rudolfstiftung, Wien, Österreich
- Fakultät für Medizin und Zahnmedizin, Donau-Privatuniversität, Krems, Österreich
| | - Wolfram Hötzenecker
- Abteilung für Dermatologie und Venerologie, Johannes-Kepler-Universität Linz, Linz, Österreich
| | - Werner Saxinger
- Abteilung für Dermatologie und Venerologie, Krankenhaus Wels-Grieskirchen, Wels-Grieskirchen, Österreich
| | - Robert Müllegger
- Abteilung für Dermatologie und Venerologie, Landesklinikum Wiener Neustadt, Wiener Neustadt, Österreich
| | - Franz Quehenberger
- Institut für Medizinische Informatik, Statistik und Dokumentation, Medizinische Universität Graz, Graz, Österreich
| | - Peter Wolf
- Abteilung für Dermatologie und Venerologie, Medizinische Universität Graz, Graz, Österreich
| |
Collapse
|
5
|
Graier T, Salmhofer W, Jonak C, Weger W, Zikeli C, Gruber B, Sator P, Prillinger K, Mlynek A, Schütz-Bergmayr M, Richter L, Ratzinger G, Sassmann C, Painsi C, Häring N, Wippel-Slupetzky K, Skvara H, Trattner H, Inzinger M, Bangert C, Ellersdorfer C, Falkensteiner K, Sadoghi B, Gruber-Wackernagel A, Hofer A, Legat F, Lange-Asschenfeldt B, Schmuth M, Vujic I, Hötzenecker W, Saxinger W, Müllegger R, Quehenberger F, Wolf P. Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004-2022. J Dtsch Dermatol Ges 2023; 21:1513-1523. [PMID: 37907427 DOI: 10.1111/ddg.15213] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2023] [Accepted: 07/21/2023] [Indexed: 11/02/2023]
Abstract
BACKGROUND AND OBJECTIVES This study analyzed the extent to which the recent introduction of more effective treatments has led to an improvement in real-world psoriasis patients. PATIENTS AND METHODS Patient characteristics and the first-year treatment effectiveness in biologic-naive patients have been analyzed since 2004 until now, irrespective of treatment switches. RESULTS Data from 2,729 patients were eligible for this analysis. The proportion of female patients increased significantly over the years from 29.9% to 36.2% (p < 0.028), while the number of patients with psoriatic arthritis declined from 36.6% to 30.0% (p < 0.001). Moreover, the duration of psoriatic disease and PASI at the start of the treatment significantly decreased. Last observation carrief forward (LOCF) analysis indicated that PASI 90 response increased from 18.9 to 44.6% at 3 months and from 32.9 to 66.8% at 12 months after treatment started. Similary, the PASI ≤ 3 rates increased from 33.2% to 66.0% at 3 months and from 41.9% to 78.9% at 12 months after the treatment started. CONCLUSIONS The continuous introduction of more efficient biologics has led to significant improvements in patient care and clinical outcomes. Though one out of three to five patients, depending on the endpoint selected, nowadays still does not achieve an entirely satisfactory treatment response (i.e., PASI 90 or PASI ≤ 3).
Collapse
Affiliation(s)
- Thomas Graier
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - Wolfgang Salmhofer
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - Constanze Jonak
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Wolfgang Weger
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - Claudia Zikeli
- Department of Dermatology and Venereology, State Hospital Wiener Neustadt, Wiener Neustadt, Austria
| | - Barbara Gruber
- Department of Dermatology and Venereology, Hospital of Wels-Grieskirchen, Wels-Grieskirchen, Austria
| | - Paul Sator
- Department of Dermatology, Clinic Hietzing, Vienna, Austria
| | - Knut Prillinger
- Department of Dermatology and Venereology, Karl-Landsteiner University, St. Pölten, Austria
| | - Alexander Mlynek
- Department of Dermatology, Hospital of Elisabethinen Linz, Linz, Austria
| | | | - Leo Richter
- Department of Dermatology and Venereology, State Hospital of Vienna Rudolfstiftung, Vienna, Austria
| | - Gudrun Ratzinger
- Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria
| | - Christoph Sassmann
- Department of Dermatology and Venereology, State Hospital Wiener Neustadt, Wiener Neustadt, Austria
| | - Clemens Painsi
- Department of Dermatology and Venereology, State Hospital Klagenfurt, Klagenfurt, Austria
| | - Nina Häring
- Department of Dermatology and Venereology, Federal Academic Teaching Hospital Feldkirch, Feldkirch, Austria
| | | | - Hans Skvara
- Department of Dermatology and Venereology, State Hospital Wiener Neustadt, Wiener Neustadt, Austria
| | - Hannes Trattner
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Martin Inzinger
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - Christina Bangert
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Christina Ellersdorfer
- Department of Dermatology and Venereology, State Hospital of Vienna Rudolfstiftung, Vienna, Austria
| | | | - Birgit Sadoghi
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | | | - Angelika Hofer
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - Franz Legat
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | | | - Matthias Schmuth
- Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria
| | - Igor Vujic
- Department of Dermatology and Venereology, State Hospital of Vienna Rudolfstiftung, Vienna, Austria
- Faculty of Medicine and Dentistry, Danube Private University, Krems, Austria
| | - Wolfram Hötzenecker
- Department of Dermatology and Venereology, Johannes Kepler University Linz, Linz, Austria
| | - Werner Saxinger
- Department of Dermatology and Venereology, Hospital of Wels-Grieskirchen, Wels-Grieskirchen, Austria
| | - Robert Müllegger
- Department of Dermatology and Venereology, State Hospital Wiener Neustadt, Wiener Neustadt, Austria
| | - Franz Quehenberger
- Institute for Medical Informatics, Statistics, and Documentation, Medical University of Graz, Graz, Austria
| | - Peter Wolf
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| |
Collapse
|
6
|
Graier T, Weger W, Jonak C, Sator P, Zikeli C, Prillinger K, Sassmann C, Gruber B, Saxinger W, Ratzinger G, Painsi C, Mlynek A, Häring N, Sadoghi B, Trattner H, Müllegger R, Quehenberger F, Salmhofer W, Wolf P. Real-world effectiveness of anti-interleukin-23 antibodies in chronic plaque-type psoriasis of patients from the Austrian Psoriasis Registry (PsoRA). Sci Rep 2022; 12:15078. [PMID: 36064563 PMCID: PMC9442573 DOI: 10.1038/s41598-022-18790-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Accepted: 08/19/2022] [Indexed: 11/09/2022] Open
Abstract
With the introduction of the latest class of biologic drugs targeting interleukin (IL)-23p19, three new, highly effective drugs can be used for the treatment of chronic plaque psoriasis. However, poorer skin improvement as well as higher rates of serious adverse events have been reported for patients under real-world conditions (outside clinical trials). This accounts especially for patients who have already been treated with biologic drugs. We therefore aimed to determine effectiveness and safety of IL-23p19 inhibitors in real-world patients by analysing data from the Psoriasis Registry Austria (PsoRA) in this observational, retrospective, multicentre cohort study. Data for 197 patients (52.3% biologic-non-naïve), who were treated with anti-IL-23p19 antibodies (127 guselkumab, 55 risankizumab and 15 tildrakizumab) for at least 3 months, were eligible for analysis. In general, biologic-non-naïve patients displayed a less favourable response to anti-IL-23 treatment as compared to biologic-naïve patients. However, after correction for previous biologic exposure, few differences in PASI improvement were detected among biologic-naïve and -non-naïve patients treated with different IL-23p19 inhibitors. This indicates that treatment effectiveness is not related to the class of the previously administered therapy in biologic-non-naïve patients. Therefore, IL-23p19 inhibitors represent a promising treatment alternative for patients who have not responded to previous biologics. However, as with other biologic agents (including IL-17 inhibitors), we did not observe an entirely satisfactory treatment response (i.e. PASI < 3 and/or PASI 75) to anti-IL-23 treatment in one out of four to five patients. Adverse events (mainly non-severe infections) were observed in 23 (11.7%) patients with no major differences regarding the administered IL-23 inhibitor or previous biologic exposure.
Collapse
Affiliation(s)
- T Graier
- Department of Dermatology and Venereology, Medical University of Graz, Auenbruggerplatz 8, 8036, Graz, Austria
| | - W Weger
- Department of Dermatology and Venereology, Medical University of Graz, Auenbruggerplatz 8, 8036, Graz, Austria
| | - C Jonak
- Medical University of Vienna, Vienna, Austria
| | - P Sator
- Clinic Hietzing, Vienna, Austria
| | - C Zikeli
- State Hospital Wiener Neustadt, Wiener Neustadt, Austria
| | - K Prillinger
- University Hospital of St. Poelten, Karl Landsteiner University of Health Sciences, Krems, Austria
| | - C Sassmann
- State Hospital Wiener Neustadt, Wiener Neustadt, Austria
| | - B Gruber
- Hospital of Wels-Grieskirchen, Wels, Austria
| | - W Saxinger
- Hospital of Wels-Grieskirchen, Wels, Austria
| | - G Ratzinger
- Medical University of Innsbruck, Innsbruck, Austria
| | - C Painsi
- State Hospital Klagenfurt, Klagenfurt, Austria
| | - A Mlynek
- Hospital of Elisabethinen, Linz, Austria
| | - N Häring
- Federal Academic Teaching Hospital, Feldkirch, Austria
| | - B Sadoghi
- Department of Dermatology and Venereology, Medical University of Graz, Auenbruggerplatz 8, 8036, Graz, Austria
| | - H Trattner
- Medical University of Vienna, Vienna, Austria
| | - R Müllegger
- State Hospital Wiener Neustadt, Wiener Neustadt, Austria
| | - F Quehenberger
- Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria
| | - W Salmhofer
- Department of Dermatology and Venereology, Medical University of Graz, Auenbruggerplatz 8, 8036, Graz, Austria
| | - Peter Wolf
- Department of Dermatology and Venereology, Medical University of Graz, Auenbruggerplatz 8, 8036, Graz, Austria.
| |
Collapse
|
7
|
Golob-Schwarzl N, Pilic J, Benezeder T, Painsi C, Wolf P. 169 Eukaryotic Translation Initiation Factors (eIFs): Potential Therapeutic Targets in Psoriasis. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
8
|
Painsi C, Schmid-Zalaudek K, Weger W, Hofmann-Wellenhof R, Wolf P, Lackner HK, Fink-Puches R, Inzinger M, Gruber B, Krenmayr K, Mlynek A, Ahlgrimm-Siess V, Salmhofer W. Die Teledermatologische Beurteilung einer Psoriasis-Zielläsion und der vom Patienten selbst berechnete PASI sind suiffizient für das Psoriasis-Monitoring. J Dtsch Dermatol Ges 2021; 19:1064-1066. [PMID: 34288474 DOI: 10.1111/ddg.14468_g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Clemens Painsi
- Abteilung für Dermatologie und Venerologie, Medizinische Universität Graz, Graz, Österreich.,Abteilung für Dermatologie, Klinikum Klagenfurt am Wörthersee, Klagenfurt, Österreich
| | - Karin Schmid-Zalaudek
- Otto-Loewi-Forschungszentrum für Gefäßbiologie, Immunologie und Entzündung Abteilung für Physiologie, Medizinische Universität Graz, Graz, Österreich
| | - Wolfgang Weger
- Abteilung für Dermatologie und Venerologie, Medizinische Universität Graz, Graz, Österreich
| | | | - Peter Wolf
- Abteilung für Dermatologie und Venerologie, Medizinische Universität Graz, Graz, Österreich
| | - Helmut Karl Lackner
- Otto-Loewi-Forschungszentrum für Gefäßbiologie, Immunologie und Entzündung Abteilung für Physiologie, Medizinische Universität Graz, Graz, Österreich
| | - Regina Fink-Puches
- Abteilung für Dermatologie und Venerologie, Medizinische Universität Graz, Graz, Österreich
| | - Martin Inzinger
- Abteilung für Dermatologie und Venerologie, Medizinische Universität Graz, Graz, Österreich
| | - Barbara Gruber
- Abteilung für Dermatologie, Klinikum Wels-Grieskirchen, Wels-Grieskirchen, Österreich
| | - Karin Krenmayr
- Abteilung für Dermatologie, Krankenhaus der Elisabethinen, Linz, Österreich
| | - Alexander Mlynek
- Abteilung für Dermatologie, Krankenhaus der Elisabethinen, Linz, Österreich
| | - Verena Ahlgrimm-Siess
- Abteilung für Dermatologie, Paracelsus Medizinische Privatuniversität Salzburg, Salzburg, Österreich
| | - Wolfgang Salmhofer
- Abteilung für Dermatologie und Venerologie, Medizinische Universität Graz, Graz, Österreich
| |
Collapse
|
9
|
Painsi C, Schmid-Zalaudek K, Weger W, Hofmann-Wellenhof R, Wolf P, Lackner HK, Fink-Puches R, Inzinger M, Gruber B, Krenmayr K, Mlynek A, Ahlgrimm-Siess V, Salmhofer W. Teledermatological assessment of one psoriasis target lesion and patient-reported-PASI are sufficient for psoriasis monitoring. J Dtsch Dermatol Ges 2021; 19:1064-1066. [PMID: 33894045 DOI: 10.1111/ddg.14468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Clemens Painsi
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria.,Department of Dermatology, State Hospital Klagenfurt, Klagenfurt, Austria
| | - Karin Schmid-Zalaudek
- Otto-Loewi Research Center for Vascular Biology, Immunology and Inflammation Division of Physiology, Medical University of Graz, Graz, Austria
| | - Wolfgang Weger
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | | | - Peter Wolf
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - Helmut Karl Lackner
- Otto-Loewi Research Center for Vascular Biology, Immunology and Inflammation Division of Physiology, Medical University of Graz, Graz, Austria
| | - Regina Fink-Puches
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - Martin Inzinger
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - Barbara Gruber
- Department of Dermatology, Hospital of Wels--Grieskirchen, Wels-Grieskirchen, Austria
| | - Karin Krenmayr
- Department of Dermatology, Krankenhaus der Elisabethinen, Linz, Austria
| | - Alexander Mlynek
- Department of Dermatology, Krankenhaus der Elisabethinen, Linz, Austria
| | - Verena Ahlgrimm-Siess
- Department of Dermatology, Paracelsus Private Medical University of Salzburg, Salzburg, Austria
| | - Wolfgang Salmhofer
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| |
Collapse
|
10
|
Graier T, Golob-Schwarzl N, Weger W, Benezeder T, Painsi C, Salmhofer W, Wolf P. Furin Expression in Patients With Psoriasis-A Patient Cohort Endangered to SARS-COV2? Front Med (Lausanne) 2021; 8:624462. [PMID: 33644099 PMCID: PMC7902756 DOI: 10.3389/fmed.2021.624462] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2020] [Accepted: 01/14/2021] [Indexed: 12/13/2022] Open
Abstract
Background: SARS-Cov2 has raised concerns among dermatologists regarding psoriasis and its respective treatments. Comorbidities, which induce the expression of the proprotease furin have been associated with severe course of COVID-19. Furin and angiotensin converting enzyme 2 (ACE2) play a major role in viral host cell entry of SARS-Cov2. Objective: To evaluate mRNA expression of Furin and ACE2 from blood cells in psoriasis patients, and whether systemic or topical treatment reduces expression levels. Methods: This observational translational study analyzed blood samples from patients from a clinical trial and samples retrieved from the biobank of the Psoriasis Registry Austria (PsoRA). Furin and ACE2 expression levels were analyzed prior to as well as 3 and 12–24 months after start of biologic treatment with either ustekinumab or secukinumab. Additionally, the study analyzed expression levels prior to, 6 days after start of dithranol treatment and 4–6 weeks after end of dithranol treatment. Results: Furin mRNA expression was significantly increased at baseline in the biologic (4.9 ± 2.6 fold, p < 0.0001) and in the dithranol group (2.7 ± 1.4 fold, p < 0.001) compared to controls. There was a trend for arthritis patients to express more furin than patients with psoriatic skin involvement only (5.26 ± 2.30 vs. 3.48 ± 2.27, p = 0.078). Analyzing furin mRNA expression after treatment initiation with secukinumab or ustekinumab revealed a normalization of levels after 3 and 12 to 24 months. Similar findings were obtained for patients treated with dithranol, with significantly decreased expression levels 6 days after start of dithranol treatment and also at follow-up, (4–6 weeks after dithranol treatment had been terminated). ACE2 expression levels did not differ from controls at any timepoint, regardless of biologic or topical treatment. Conclusion: Significantly overexpressed levels of furin were observed in untreated patients, and, thus, these patients may be at risk for infection and a severe course of COVID-19. However, the data indicate that successful therapeutic intervention in psoriasis, by systemic biologic or topical treatment, can efficiently reduce furin levels in blood cells, possibly limiting the risk of psoriasis patients for a severe COVID-19 course. Clinical Trial Registration:ClinicalTrials.gov, identifier NCT02752672.
Collapse
Affiliation(s)
- Thomas Graier
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - Nicole Golob-Schwarzl
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - Wolfgang Weger
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - Theresa Benezeder
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - Clemens Painsi
- Department of Dermatology and Venereology, State Hospital, Klagenfurt, Austria
| | - Wolfgang Salmhofer
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - Peter Wolf
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| |
Collapse
|
11
|
Graier T, Salmhofer W, Jonak C, Weger W, Kölli C, Gruber B, Sator PG, Prillinger K, Mlynek A, Schütz-Bergmayr M, Richter L, Ratzinger G, Painsi C, Selhofer S, Häring N, Wippel-Slupetzky K, Skvara H, Trattner H, Tanew A, Inzinger M, Tatarski R, Bangert C, Ellersdorfer C, Lichem R, Gruber-Wackernagel A, Hofer A, Legat F, Schmiedberger E, Strohal R, Lange-Asschenfeldt B, Schmuth M, Vujic I, Hoetzenecker W, Trautinger F, Saxinger W, Müllegger R, Quehenberger F, Wolf P. Biologic drug survival rates in the era of anti-interleukin-17 antibodies: a time-period-adjusted registry analysis. Br J Dermatol 2020; 184:1094-1105. [PMID: 33289075 PMCID: PMC8248155 DOI: 10.1111/bjd.19701] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/28/2020] [Indexed: 12/22/2022]
Abstract
Background Drug survival rates reflect efficacy and safety and may be influenced by the availability of alternative treatment options. Little is known about time‐dependent drug survival in psoriasis and the effect of increasing numbers of biologic treatment options. Objectives To determine whether drug survival is influenced by the availability of treatment options and by factors such as gender, psoriatic arthritis or previous biologic treatment. Methods This observational, retrospective, multicentre cohort study analysed data from patients registered in the Austrian Psoriasis Registry (PsoRA) who were treated with biologics between 1 January 2015 and 30 November 2019. Results A total of 1572 patients who received 1848 treatment cycles were included in this analysis. The highest long‐term Psoriasis Area and Severity Index improvement was observed after treatment with ixekizumab, followed by ustekinumab and secukinumab, adalimumab and etanercept. Overall, ustekinumab surpassed all other biologics in drug survival up to 48 months. However, when adjusted for biologic naïvety, its superiority vanished and drug survival rates were similar for ixekizumab (91·6%), secukinumab (90·2%) and ustekinumab (92·8%), all of them superior to adalimumab (76·5%) and etanercept (71·9%) at 12 months and beyond. Besides biologic non‐naïvety (2·10, P < 0·001), the introduction of a new drug such as secukinumab or ixekizumab (relative hazard ratio 1·6, P = 0·001) and female gender (1·50, P = 0·019) increased the risk of treatment discontinuation overall, whereas psoriatic arthritis did not (1·12, P = 0·21). Conclusions The time‐dependent availability of drugs should be considered when analysing and comparing drug survival. Previous biologic exposure significantly influences drug survival. Women are more likely to stop treatment.
What is already known about this topic?
Female gender and previous biologic exposure have been discussed as predictors for decreased drug survival in patients with psoriasis, but it remains unknown whether a time‐dependent increased availability of treatment options alters biologic drug survival.
What does this study add?
The increased availability of alternative biologic treatments over time leads to an elevated risk for treatment discontinuation overall; therefore, drug survival analysis has to be time adjusted. Moreover, the study reveals that the impact of previous biologic treatment on drug survival is tremendous and confirms worse drug survival in female patients.
Linked Comment: Gniadecki. Br J Dermatol 2021; 184:996–997.
Collapse
Affiliation(s)
- T Graier
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - W Salmhofer
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - C Jonak
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - W Weger
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - C Kölli
- Department of Dermatology and Venereology, State Hospital, Wiener Neustadt, Austria
| | - B Gruber
- Department of Dermatology and Venereology, Hospital of Wels-Grieskirchen, Wels-Grieskirchen, Austria
| | - P G Sator
- Department of Dermatology, Hietzing Hospital, Vienna, Austria
| | - K Prillinger
- Department of Dermatology and Venereology, University Hospital St Pölten, St Pölten, Austria
| | - A Mlynek
- Department of Dermatology, Hospital of Elisabethinen, Linz, Austria
| | - M Schütz-Bergmayr
- Department of Dermatology and Venereology, Kepler University Hospital, Linz, Austria
| | - L Richter
- Department of Dermatology and Venereology, State Hospital of Vienna Rudolfstiftung, Vienna, Austria
| | - G Ratzinger
- Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria
| | - C Painsi
- Department of Dermatology and Venereology, State Hospital, Klagenfurt, Austria
| | - S Selhofer
- Department of Dermatology and Allergology, Paracelsus Medical University, Salzburg, Austria
| | - N Häring
- Department of Dermatology and Venereology, Federal Academic Teaching Hospital, Feldkirch, Austria
| | | | - H Skvara
- Department of Dermatology and Venereology, State Hospital, Wiener Neustadt, Austria
| | - H Trattner
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - A Tanew
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - M Inzinger
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - R Tatarski
- Department of Dermatology and Allergology, Paracelsus Medical University, Salzburg, Austria
| | - C Bangert
- Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - C Ellersdorfer
- Department of Dermatology and Venereology, State Hospital of Vienna Rudolfstiftung, Vienna, Austria
| | - R Lichem
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - A Gruber-Wackernagel
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - A Hofer
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - F Legat
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| | - E Schmiedberger
- Institute for Medical Informatics, Statistics, and Documentation, Medical University of Graz, Graz, Austria
| | - R Strohal
- Department of Dermatology and Venereology, Federal Academic Teaching Hospital, Feldkirch, Austria
| | | | - M Schmuth
- Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Innsbruck, Austria
| | - I Vujic
- Department of Dermatology and Venereology, State Hospital of Vienna Rudolfstiftung, Vienna, Austria
| | - W Hoetzenecker
- Department of Dermatology and Venereology, Kepler University Hospital, Linz, Austria
| | - F Trautinger
- Department of Dermatology and Venereology, University Hospital St Pölten, St Pölten, Austria
| | - W Saxinger
- Department of Dermatology and Venereology, Hospital of Wels-Grieskirchen, Wels-Grieskirchen, Austria
| | - R Müllegger
- Department of Dermatology and Venereology, State Hospital, Wiener Neustadt, Austria
| | - F Quehenberger
- Institute for Medical Informatics, Statistics, and Documentation, Medical University of Graz, Graz, Austria
| | - P Wolf
- Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria
| |
Collapse
|
12
|
Sconocchia T, Hochgerner M, Schwarzenberger E, Tam-Amersdorfer C, Borek I, Benezeder T, Bauer T, Zyulina V, Painsi C, Passegger C, Wolf P, Sibilia M, Strobl H. Bone morphogenetic protein signaling regulates skin inflammation via modulating dendritic cell function. J Allergy Clin Immunol 2020; 147:1810-1822.e9. [PMID: 33250156 DOI: 10.1016/j.jaci.2020.09.038] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Revised: 08/22/2020] [Accepted: 09/18/2020] [Indexed: 12/11/2022]
Abstract
BACKGROUND Bone morphogenetic proteins (BMPs) are members of the TGF-β family that signal via the BMP receptor (BMPR) signaling cascade, distinct from canonical TGF-β signaling. BMP downstream signaling is strongly induced within epidermal keratinocytes in cutaneous psoriatic lesions, and BMP7 instructs monocytic cells to acquire characteristics of psoriasis-associated Langerhans dendritic cells (DCs). Regulatory T (Treg)-cell numbers strongly increase during psoriatic skin inflammation and were recently shown to limit psoriatic skin inflammation. However, the factors mediating Treg-cell accumulation in psoriatic skin currently remain unknown. OBJECTIVE We sought to investigate the role of BMP signaling in Treg-cell accumulation in psoriasis. METHODS The following methods were used: immunohistology of patients and healthy controls; ex vivo models of Treg-cell generation in the presence or absence of Langerhans cells; analysis of BMP versus canonical TGF-β signaling in DCs and Treg cells; and modeling of psoriatic skin inflammation in mice lacking the BMPR type 1a in CD11c+ cells. RESULTS We here demonstrated a positive correlation between Treg-cell numbers and epidermal BMP7 expression in cutaneous psoriatic lesions and show that unlike Treg cells from healthy skin, a portion of inflammation-associated Treg cells exhibit constitutive-active BMP signaling. We further found that BMPR signaling licenses inflammation-associated Langerhans cell/DC to gain an enhanced capacity to promote Treg cells via BMPR-mediated CD25 induction and that this effect is associated with reduced skin inflammation. CONCLUSIONS Psoriatic lesions are marked by constitutive high BMP7/BMPR signaling in keratinocytes, which instructs inflammatory DCs to gain enhanced Treg-cell-stimulatory activity. Locally secreted BMP7 can directly promote Treg-cell generation through the BMP signaling cascade.
Collapse
Affiliation(s)
- Tommaso Sconocchia
- Otto Loewi Research Center, Division of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria
| | - Mathias Hochgerner
- Institute of Cancer Research, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
| | - Elke Schwarzenberger
- Otto Loewi Research Center, Division of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria
| | - Carmen Tam-Amersdorfer
- Otto Loewi Research Center, Division of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria
| | - Izabela Borek
- Otto Loewi Research Center, Division of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria
| | - Theresa Benezeder
- Department of Dermatology, Medical University of Graz, Graz, Austria
| | - Thomas Bauer
- Institute of Cancer Research, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
| | - Victoria Zyulina
- Otto Loewi Research Center, Division of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria
| | - Clemens Painsi
- Department of Dermatology, State Hospital Klagenfurt, Klagenfurt, Austria
| | - Christina Passegger
- Otto Loewi Research Center, Division of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria
| | - Peter Wolf
- Department of Dermatology, Medical University of Graz, Graz, Austria
| | - Maria Sibilia
- Institute of Cancer Research, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
| | - Herbert Strobl
- Otto Loewi Research Center, Division of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria.
| |
Collapse
|
13
|
Benezeder T, Painsi C, Patra V, Dey S, Holcmann M, Lange-Asschenfeldt B, Sibilia M, Wolf P. Dithranol targets keratinocytes, their crosstalk with neutrophils and inhibits the IL-36 inflammatory loop in psoriasis. eLife 2020; 9:e56991. [PMID: 32484435 PMCID: PMC7266641 DOI: 10.7554/elife.56991] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Accepted: 05/18/2020] [Indexed: 12/18/2022] Open
Abstract
Despite the introduction of biologics, topical dithranol (anthralin) has remained one of the most effective anti-psoriatic agents. Serial biopsies from human psoriatic lesions and both the c-Jun/JunB and imiquimod psoriasis mouse model allowed us to study the therapeutic mechanism of this drug. Top differentially expressed genes in the early response to dithranol belonged to keratinocyte and epidermal differentiation pathways and IL-1 family members (i.e. IL36RN) but not elements of the IL-17/IL-23 axis. In human psoriatic response to dithranol, rapid decrease in expression of keratinocyte differentiation regulators (e.g. involucrin, SERPINB7 and SERPINB13), antimicrobial peptides (e.g. ß-defensins like DEFB4A, DEFB4B, DEFB103A, S100 proteins like S100A7, S100A12), chemotactic factors for neutrophils (e.g. CXCL5, CXCL8) and neutrophilic infiltration was followed with much delay by reduction in T cell infiltration. Targeting keratinocytes rather than immune cells may be an alternative approach in particular for topical anti-psoriatic treatment, an area with high need for new drugs.
Collapse
Affiliation(s)
| | - Clemens Painsi
- State Hospital KlagenfurtKlagenfurt am WörtherseeAustria
| | - VijayKumar Patra
- Department of Dermatology, Medical University of GrazGrazAustria
| | - Saptaswa Dey
- Department of Dermatology, Medical University of GrazGrazAustria
| | - Martin Holcmann
- Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of ViennaViennaAustria
| | | | - Maria Sibilia
- Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of ViennaViennaAustria
| | - Peter Wolf
- Department of Dermatology, Medical University of GrazGrazAustria
| |
Collapse
|
14
|
Borek I, Köffel R, Feichtinger J, Spies M, Glitzner-Zeis E, Hochgerner M, Sconocchia T, Krump C, Tam-Amersdorfer C, Passegger C, Benezeder T, Tittes J, Redl A, Painsi C, Thallinger GG, Wolf P, Stary G, Sibilia M, Strobl H. BMP7 aberrantly induced in the psoriatic epidermis instructs inflammation-associated Langerhans cells. J Allergy Clin Immunol 2019; 145:1194-1207.e11. [PMID: 31870764 DOI: 10.1016/j.jaci.2019.12.011] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2019] [Revised: 12/08/2019] [Accepted: 12/13/2019] [Indexed: 12/31/2022]
Abstract
BACKGROUND Epidermal hyperplasia represents a morphologic hallmark of psoriatic skin lesions. Langerhans cells (LCs) in the psoriatic epidermis engage with keratinocytes (KCs) in tight physical interactions; moreover, they induce T-cell-mediated immune responses critical to psoriasis. OBJECTIVE This study sought to improve the understanding of epidermal factors in psoriasis pathogenesis. METHODS BMP7-LCs versus TGF-β1-LCs were phenotypically characterized and their functional properties were analyzed using flow cytometry, cell kinetic studies, co-culture with CD4 T cells, and cytokine measurements. Furthermore, immunohistology of healthy and psoriatic skin was performed. Additionally, in vivo experiments with Junf/fJunBf/fK5cre-ERT mice were carried out to assess the role of bone morphogenetic protein (BMP) signaling in psoriatic skin inflammation. RESULTS This study identified a KC-derived signal (ie, BMP signaling) to promote epidermal changes in psoriasis. Whereas BMP7 is strictly confined to the basal KC layer in the healthy skin, it is expressed at high levels throughout the lesional psoriatic epidermis. BMP7 instructs precursor cells to differentiate into LCs that phenotypically resemble psoriatic LCs. These BMP7-LCs exhibit proliferative activity and increased sensitivity to bacterial stimulation. Moreover, aberrant high BMP signaling in the lesional epidermis is mediated by a KC intrinsic mechanism, as suggested from murine data and clinical outcome after topical antipsoriatic treatment in human patients. CONCLUSIONS These data indicate that available TGF-β family members within the lesional psoriatic epidermis preferentially signal through the canonical BMP signaling cascade to instruct inflammatory-type LCs and to promote psoriatic epidermal changes. Targeting BMP signaling might allow to therapeutically interfere with cutaneous psoriatic manifestations.
Collapse
Affiliation(s)
- Izabela Borek
- Otto Loewi Research Center, Chair of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria
| | - René Köffel
- Institute of Anatomy, University of Bern, Bern, Switzerland
| | - Julia Feichtinger
- Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center for Cell Signaling, Metabolism and Aging, Medical University of Graz, Graz, Austria
| | - Melanie Spies
- Otto Loewi Research Center, Chair of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria
| | - Elisabeth Glitzner-Zeis
- Institute of Cancer Research, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
| | - Mathias Hochgerner
- Institute of Cancer Research, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
| | - Tommaso Sconocchia
- Otto Loewi Research Center, Chair of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria
| | - Corinna Krump
- Otto Loewi Research Center, Chair of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria
| | - Carmen Tam-Amersdorfer
- Otto Loewi Research Center, Chair of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria
| | - Christina Passegger
- Otto Loewi Research Center, Chair of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria
| | - Theresa Benezeder
- Department of Dermatology, Medical University of Graz, Graz, Austria
| | - Julia Tittes
- Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Anna Redl
- Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Clemens Painsi
- Department of Dermatology, State Hospital Klagenfurt, Klagenfurt, Austria
| | - Gerhard G Thallinger
- Institute of Computational Biotechnology, Graz University of Technology, Graz, Austria; Omics Center Graz, BioTechMed Graz, Graz, Austria
| | - Peter Wolf
- Department of Dermatology, Medical University of Graz, Graz, Austria
| | - Georg Stary
- Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Medical University of Vienna, Vienna, Austria
| | - Maria Sibilia
- Institute of Cancer Research, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria
| | - Herbert Strobl
- Otto Loewi Research Center, Chair of Immunology and Pathophysiology, Medical University of Graz, Graz, Austria.
| |
Collapse
|
15
|
Benezeder T, Painsi C, Wagner K, Lange-Asschenfeldt B, Wolf P. 1007 Dithranol-treated psoriasis lesions show unique early changes in gene expression profile. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.1083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
16
|
Painsi C, Hesterberg K, Lademann J, Knorr D, Patzelt A, Vandersee S, Meinke MC, Richter H, Bob A, Knorr F, Quehenberger F, Lange-Asschenfeldt B. Influence of Storage and Preservation Techniques on Egg-Derived Carotenoids: A Substantial Source for Cutaneous Antioxidants. Skin Pharmacol Physiol 2019; 32:65-71. [PMID: 30612131 DOI: 10.1159/000493147] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2018] [Accepted: 08/13/2018] [Indexed: 11/19/2022]
Abstract
Antioxidants like carotenoids play a major role in the prevention of the destructive influence of free radicals in our skin. Carotenoids, as well as all other antioxidants, are substantial substances which must be supplied by nutrition. Resonance Raman spectroscopy (RRS) allows measurement of the carotenoid content of eggs, representing a rich carotenoid source in our nutrition. A previous study showed that eggs from organic production contain higher carotenoid levels in contrast to eggs from conventionally housed chicken. The uptake of these organically produced eggs led to an increased antioxidant concentration in the skin. In this study, the effects of different storage modalities, conservation techniques, and the effects of food processing on the carotenoid levels in eggs were investigated with RRS. Common storage modalities and preservation techniques showed only a limited influence on egg-derived carotenoid concentrations. However, a colder environment (at least for shell eggs) and high-pressure preservation had the best preservative influence on the carotenoid content. Surprisingly, food processing such as boiling increased the carotenoid concentration in eggs, whilst broiling destroyed the carotenoids almost completely. In conclusion, RRS is suitable for monitoring egg-derived carotenoid levels, and carotenoid levels in eggs are generally stable under common storage and preservation modalities. Boiling in contrast to broiling of eggs might be superior in terms of carotenoid preservation within food processing.
Collapse
Affiliation(s)
- Clemens Painsi
- Department of Dermatology and Venerology, State Hospital Klagenfurt, Klagenfurt, Austria.,Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria
| | - Karoline Hesterberg
- Department of Process Sciences, Berlin University of Technology, Berlin, Germany
| | - Jürgen Lademann
- Department of Dermatology, Allergology and Venerology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Dietrich Knorr
- Department of Food Biotechnology and Food Process Engineering, Berlin University of Technology, Berlin, Germany
| | - Alexa Patzelt
- Department of Dermatology, Allergology and Venerology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Staffan Vandersee
- Department of Dermatology, Allergology and Venerology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Martina C Meinke
- Department of Dermatology, Allergology and Venerology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Heike Richter
- Department of Dermatology, Allergology and Venerology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Adrienne Bob
- Department of Dermatology, Allergology and Venerology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Fanny Knorr
- Department of Dermatology, Allergology and Venerology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Franz Quehenberger
- Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria
| | - Bernhard Lange-Asschenfeldt
- Department of Dermatology and Venerology, State Hospital Klagenfurt, Klagenfurt, Austria, .,Department of Dermatology, Allergology and Venerology, Charité - Universitätsmedizin Berlin, Berlin, Germany,
| |
Collapse
|
17
|
Wolf P, Weger W, Legat F, Painsi C, Saxinger W, Müllegger R, Sator P, Ratzinger G, Selhofer S, Richter L, Salmhofer W, Lange-Asschenfeldt B, Trautinger F, Mlynek A, Strohal R, Augustin M, Quehenberger F. Quality of life and treatment goals in psoriasis from the patient perspective: results of an Austrian cross-sectional survey. J Dtsch Dermatol Ges 2018; 16:981-990. [PMID: 30117711 DOI: 10.1111/ddg.13613] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Accepted: 02/06/2018] [Indexed: 11/29/2022]
Abstract
BACKGROUND Patients with psoriasis experience impairment in quality of life. Thus, high-quality dermatological care is of particular importance. PATIENTS AND METHODS We performed a nationwide cross-sectional survey in Austria (BQSAustria Psoriasis 2014/2015) with a special focus on quality of life and satisfaction with treatment among psoriasis patients predominantly treated at tertiary care centers. RESULTS Overall, 70.2 % of 1,184 patients reported impaired quality of life (DLQI 2-5: 29.4 %; 6-10: 19.3 %; 11-15: 11.5 %; 16-20: 5.2 % and > 20: 4.9 %) despite treatment over the preceding four weeks (topical treatment in 88.2 % of cases and/or systemic treatment in 38.7 %). On average, none of the 25 defined subjective treatment goals was achieved to a sufficient degree. In particular, 82.2 % of patients continued to have pruritus despite treatment, which was highly significantly associated with a poor general health status over the preceding week (Spearman's rank correlation; p = 1.1e-45), the extent of body surface area (p = 3.2e-11) and scalp area (p = 3.2e-11) affected, as well as pain (p = 2.3e-22). Treatment with a biologic was significantly correlated with higher patient satisfaction (Wilcoxon-Test, p = 2.0e-16). CONCLUSIONS Despite dermatological care, the majority of Austrian psoriasis patients continues to experience impaired quality of life; there is potential for improvement in the achievement of treatment goals.
Collapse
Affiliation(s)
- Peter Wolf
- Department of Dermatology and Venereology, Graz Medical University, Graz, Austria
| | - Wolfgang Weger
- Department of Dermatology and Venereology, Graz Medical University, Graz, Austria
| | - Franz Legat
- Department of Dermatology and Venereology, Graz Medical University, Graz, Austria.,Kurhaus Bad Gleichenberg, Bad Gleichenberg, Austria
| | - Clemens Painsi
- Department of Dermatology and Venereology, Graz Medical University, Graz, Austria.,Department of Dermatology and Venereology, Klagenfurt Medical Center, Klagenfurt, Austria
| | - Werner Saxinger
- Department of Dermatology and Venereology, Wels-Grieskirchen Medical Center, Wels, Austria
| | - Robert Müllegger
- Department of Dermatology and Venereology, State Medical Center, Wiener Neustadt, Austria
| | - Paul Sator
- Department of Dermatology, Hietzing Hospital, Vienna, Austria
| | - Gudrun Ratzinger
- Department of Dermatology, Venereology and Allergology, Medical University of Innsbruck, Austria
| | - Sylvia Selhofer
- Department of Dermatology, Paracelsus Private Medical University, Salzburg, Austria
| | - Leo Richter
- Department of Dermatology and Venereology, The Rudolfstiftung Hospital, Vienna, Austria
| | - Wolfgang Salmhofer
- Department of Dermatology and Venereology, Graz Medical University, Graz, Austria
| | | | - Franz Trautinger
- Department of Dermatology and Venereology, University Medical Center St. Pölten, Karl Landsteiner University of Health Sciences, Krems, Austria
| | - Alexander Mlynek
- Department of Dermatology, Elisabethinen Medical Center, Linz, Austria
| | - Robert Strohal
- Department of Dermatology and Venereology, State Hospital and Academic Teaching Hospital Feldkirch, Feldkirch, Austria
| | - Matthias Augustin
- Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Franz Quehenberger
- Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria
| |
Collapse
|
18
|
Wolf P, Weger W, Legat F, Painsi C, Saxinger W, Müllegger R, Sator P, Ratzinger G, Selhofer S, Richter L, Salmhofer W, Lange‐Asschenfeldt B, Trautinger F, Mlynek A, Strohal R, Augustin M, Quehenberger F. Lebensqualität und Behandlungsziele bei Psoriasis aus Patientensicht: Ergebnisse eines österreichweiten Querschnitt‐Survey. J Dtsch Dermatol Ges 2018; 16:981-991. [DOI: 10.1111/ddg.13613_g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2017] [Accepted: 02/06/2018] [Indexed: 11/26/2022]
Affiliation(s)
- Peter Wolf
- Universitätsklinik für Dermatologie und VenerologieMedizinische Universität Graz Graz Österreich
| | - Wolfgang Weger
- Universitätsklinik für Dermatologie und VenerologieMedizinische Universität Graz Graz Österreich
| | - Franz Legat
- Universitätsklinik für Dermatologie und VenerologieMedizinische Universität Graz Graz Österreich
- Das Kurhaus Bad GleichenbergBad Gleichenberg Österreich
| | - Clemens Painsi
- Universitätsklinik für Dermatologie und VenerologieMedizinische Universität Graz Graz Österreich
- Abteilung für Dermatologie und VenerologieKlinikum Klagenfurt am Wörthersee Klagenfurt Österreich
| | - Werner Saxinger
- Abteilung für Haut‐ und GeschlechtskrankheitenKlinikum Wels‐Grieskirchen Wels Österreich
| | - Robert Müllegger
- Abteilung für Dermatologie und VenerologieLandesklinikum Wiener Neustadt Wiener Neustadt Österreich
| | - Paul Sator
- Dermatologische AbteilungKrankenhaus Hietzing Wien Österreich
| | - Gudrun Ratzinger
- Universitätsklinik für DermatologieVenerologie und AllergologieMedizinische Universität Innsbruck Innsbruck Österreich
| | - Sylvia Selhofer
- Universitätsklinik für DermatologieParacelsus Medizinische Privatuniversität Salzburg Salzburg Österreich
| | - Leo Richter
- Abteilung für Dermatologie und VenerologieKrankenanstalt Wien‐Rudolfstiftung Wien Österreich
| | - Wolfgang Salmhofer
- Universitätsklinik für Dermatologie und VenerologieMedizinische Universität Graz Graz Österreich
| | | | - Franz Trautinger
- Abteilung für Haut‐ und GeschlechtskrankheitenUniversitätsklinikum St. Pölten, Karl Landsteiner Privatuniversität für Gesundheitswissenschaften Krems Österreich
| | - Alexander Mlynek
- Abteilung für DermatologieOrdensklinikum Linz – Elisabethinen Linz Österreich
| | - Robert Strohal
- Abteilung für Dermatologie und VenerologieLandeskrankenhaus Feldkirch – Akademisches Lehrspital Feldkirch Österreich
| | - Matthias Augustin
- Institut für Versorgungsforschung in der Dermatologie und bei PflegeberufenUniversitätsklinikum Hamburg‐Eppendorf Hamburg Deutschland
| | - Franz Quehenberger
- Institut für Medizinische InformatikStatistik und DokumentationMedizinische Universität Graz, Graz Österreich
| |
Collapse
|
19
|
Niederkorn A, Frühauf J, Schwantzer G, Wutte N, Painsi C, Werner S, Stradner M, Berghold A, Hermann J, Aberer E. CXCL13 is an activity marker for systemic, but not cutaneous lupus erythematosus: a longitudinal cohort study. Arch Dermatol Res 2018; 310:485-493. [DOI: 10.1007/s00403-018-1836-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2018] [Revised: 04/16/2018] [Accepted: 04/25/2018] [Indexed: 12/20/2022]
|
20
|
Krediet JT, Kanitakis J, Bob A, Schmitter J, Krediet AC, Röwert J, Stockfleth E, Painsi C, Hügel R, Terhorst D, Lange-Asschenfeldt B. Prognostic value of the area and density of lymphatic vessels in cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 2018; 14:1114-1121. [PMID: 27879093 DOI: 10.1111/ddg.12880] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2015] [Accepted: 09/21/2015] [Indexed: 11/27/2022]
Abstract
BACKGROUND AND OBJECTIVES Cutaneous squamous cell carcinoma (SCC) is known for its capacity to metastasize via lymphatic vessels. In recent studies, the level of lymphangiogenesis has been reported as a potential prognostic factor for several skin tumors. The aim of this study was to quantify lymphangiogenesis in SCC using either computer-assisted image analysis or the Chalkley count technique. Vascular parameters were evaluated and compared with respect to their predictive power for tumor metastasis. PATIENT AND METHODS In this case-control study, clinical and histological data of 15 metastatic and 15 nonmetastatic SCC patients were retrospectively analyzed. SCC samples were immunostained for the lymphatic endothelial marker D2-40 and the panvascular marker CD31, and analyzed using computer-assisted morphometric image analyses within hot spots as well as the digitalized Chalkley counting method. RESULTS Lymphatic vessel density, relative lymphatic vessel area, and lymphatic Chalkley count were significantly elevated in metastatic SCC. Tumor thickness was significantly higher in metastatic SCC, and had the highest predictive power for metastatic disease. Tumor thickness was a significant predictor of lymphangiogenic parameters. CONCLUSIONS Lymphangiogenesis is elevated in metastatic SCC but its extent is influenced by tumor thickness. Tumor thickness remains the most reliable predictive factor for metastatic disease.
Collapse
Affiliation(s)
- Jorien Tannette Krediet
- Skin Cancer Center Charité, Department of Dermatology and Allergy, Charité-Universitaetsmedizin Berlin, Berlin, Germany
| | - Jean Kanitakis
- Department of Dermatology, Ed. Herriot Hospital, Lyon, France
| | - Adrienne Bob
- Skin Cancer Center Charité, Department of Dermatology and Allergy, Charité-Universitaetsmedizin Berlin, Berlin, Germany
| | - Julia Schmitter
- Skin Cancer Center Charité, Department of Dermatology and Allergy, Charité-Universitaetsmedizin Berlin, Berlin, Germany
| | - Annelot Carine Krediet
- Department of Anesthesiology, University Medical Centre Utrecht, Utrecht, The Netherlands
| | - Joachim Röwert
- Skin Cancer Center Charité, Department of Dermatology and Allergy, Charité-Universitaetsmedizin Berlin, Berlin, Germany
| | - Eggert Stockfleth
- Skin Cancer Center Charité, Department of Dermatology and Allergy, Charité-Universitaetsmedizin Berlin, Berlin, Germany
| | - Clemens Painsi
- Department of Dermatology and Venereology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Austria
| | - Rainer Hügel
- Department of Dermatology and Venereology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Austria
| | - Dorothea Terhorst
- Skin Cancer Center Charité, Department of Dermatology and Allergy, Charité-Universitaetsmedizin Berlin, Berlin, Germany
| | - Bernhard Lange-Asschenfeldt
- Skin Cancer Center Charité, Department of Dermatology and Allergy, Charité-Universitaetsmedizin Berlin, Berlin, Germany.,Department of Dermatology and Venereology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Austria
| |
Collapse
|
21
|
Affiliation(s)
- K Hammer
- Department of Dermatology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Feschnigstraße 11, A-9020, Klagenfurt, Austria
| | - R Hügel
- Department of Dermatology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Feschnigstraße 11, A-9020, Klagenfurt, Austria
| | - B Lange-Asschenfeldt
- Department of Dermatology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Feschnigstraße 11, A-9020, Klagenfurt, Austria.,Department of Dermatology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - C Painsi
- Department of Dermatology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Feschnigstraße 11, A-9020, Klagenfurt, Austria
| |
Collapse
|
22
|
Painsi C, Hirtenfelder A, Lange-Asschenfeldt B, Quehenberger F, Wolf P. The Prevalence of Periodontitis Is Increased in Psoriasis and Linked to Its Inverse Subtype. Skin Pharmacol Physiol 2017; 30:324-328. [DOI: 10.1159/000481544] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2017] [Accepted: 09/15/2017] [Indexed: 01/06/2023]
|
23
|
Painsi C, Hirtenfelder A, Lange-Asschenfeldt B, Quehenberger F, Wolf P. 036 The prevalence of periodontitis is increased in psoriasis and linked to its inverse subtype. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
24
|
Benezeder T, Painsi C, Lange-Asschenfeldt B, Hammer K, Wolf P. 047 Chemokine ligand 22 (CCL22) plasma levels correlate with disease severity and predict response to dithranol treatment in patients with psoriasis. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.07.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
25
|
Painsi C, Lange-Asschenfeldt B. Image Gallery: Pink papules within a tattoo linked to Mycobacterium chelonae infection. Br J Dermatol 2017; 177:e1. [PMID: 28731256 DOI: 10.1111/bjd.15481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- C Painsi
- Department of Dermatology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Feschnigstraße 11, A-9020, Klagenfurt, Austria
| | - B Lange-Asschenfeldt
- Department of Dermatology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Feschnigstraße 11, A-9020, Klagenfurt, Austria.,Department of Dermatology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
26
|
Painsi C, Aubell K, Wolf P, Hügel R, Lange-Asschenfeldt B. A case of Schöpf-Schulz-Passarge syndrome caused by c.1135C>T WNT10A missense mutation. J Dtsch Dermatol Ges 2017; 15:455-457. [DOI: 10.1111/ddg.13183] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Clemens Painsi
- Department of Dermatology; State Hospital Klagenfurt; Klagenfurt am Wörthersee Austria
| | - Kristina Aubell
- Institute of Human Genetics; Medical University of Graz; Graz Austria
| | - Peter Wolf
- Department of Dermatology; Medical University of Graz; Graz Austria
| | - Rainer Hügel
- Department of Dermatology; State Hospital Klagenfurt; Klagenfurt am Wörthersee Austria
| | - Bernhard Lange-Asschenfeldt
- Department of Dermatology; State Hospital Klagenfurt; Klagenfurt am Wörthersee Austria
- Department of Dermatology; Charité - Universitätsmedizin Berlin; Berlin Germany
| |
Collapse
|
27
|
Painsi C, Aubell K, Wolf P, Hügel R, Lange-Asschenfeldt B. Ein Fall von Schöpf-Schulz-Passarge-Syndrom verursacht durch eine c.1135C>T WNT10A Missense-Mutation. J Dtsch Dermatol Ges 2017; 15:454-456. [DOI: 10.1111/ddg.13183_g] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Clemens Painsi
- Abteilung für Dermatologie und Venerologie; Klinikum Klagenfurt; Klagenfurt am Wörthersee Österreich
| | - Kristina Aubell
- Institut für Humangenetik; Medizinische Universität Graz; Graz Österreich
| | - Peter Wolf
- Universitätsklinik für Dermatologie und Venerologie; Medizinische Universität Graz; Graz Österreich
| | - Rainer Hügel
- Abteilung für Dermatologie und Venerologie; Klinikum Klagenfurt; Klagenfurt am Wörthersee Österreich
| | - Bernhard Lange-Asschenfeldt
- Abteilung für Dermatologie und Venerologie; Klinikum Klagenfurt; Klagenfurt am Wörthersee Österreich
- Klinik für Dermatologie; Venerologie und Allergologie; Charité - Universitätsmedizin Berlin; Berlin Deutschland
| |
Collapse
|
28
|
Krediet JT, Kanitakis J, Bob A, Schmitter J, Carine Krediet A, Röwert J, Stockfleth E, Painsi C, Hügel R, Terhorst D, Lange‐Asschenfeldt B. Prognostischer Wert der Fläche und Dichte von Lymphgefäßen bei kutanem Plattenepithelkarzinom. J Dtsch Dermatol Ges 2016; 14:1116-1124. [DOI: 10.1111/ddg.12880_g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2015] [Accepted: 09/21/2015] [Indexed: 11/30/2022]
Affiliation(s)
- Jorien Tannette Krediet
- Skin Cancer Center Charité, Department of Dermatology and Allergy, Charité‐Universitaetsmedizin Berlin, Berlin, Germany (Hauttumorcentrum Charité, Klinik für Dermatologie, Venerologie und Allergologie, Charité‐Universitätsmedizin Berlin, Berlin, Deutschland)
| | - Jean Kanitakis
- Department of Dermatology, Ed. Herriot Hospital, Lyon, Frankreich
| | - Adrienne Bob
- Skin Cancer Center Charité, Department of Dermatology and Allergy, Charité‐Universitaetsmedizin Berlin, Berlin, Germany (Hauttumorcentrum Charité, Klinik für Dermatologie, Venerologie und Allergologie, Charité‐Universitätsmedizin Berlin, Berlin, Deutschland)
| | - Julia Schmitter
- Skin Cancer Center Charité, Department of Dermatology and Allergy, Charité‐Universitaetsmedizin Berlin, Berlin, Germany (Hauttumorcentrum Charité, Klinik für Dermatologie, Venerologie und Allergologie, Charité‐Universitätsmedizin Berlin, Berlin, Deutschland)
| | | | - Joachim Röwert
- Skin Cancer Center Charité, Department of Dermatology and Allergy, Charité‐Universitaetsmedizin Berlin, Berlin, Germany (Hauttumorcentrum Charité, Klinik für Dermatologie, Venerologie und Allergologie, Charité‐Universitätsmedizin Berlin, Berlin, Deutschland)
| | - Eggert Stockfleth
- Skin Cancer Center Charité, Department of Dermatology and Allergy, Charité‐Universitaetsmedizin Berlin, Berlin, Germany (Hauttumorcentrum Charité, Klinik für Dermatologie, Venerologie und Allergologie, Charité‐Universitätsmedizin Berlin, Berlin, Deutschland)
| | - Clemens Painsi
- Department of Dermatology and Venereology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Austria (Abteilung für Dermatologie und Venerologie, Klinikum Klagenfurt, Klagenfurt am Wörthersee, Österreich)
| | - Rainer Hügel
- Department of Dermatology and Venereology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Austria (Abteilung für Dermatologie und Venerologie, Klinikum Klagenfurt, Klagenfurt am Wörthersee, Österreich)
| | - Dorothea Terhorst
- Skin Cancer Center Charité, Department of Dermatology and Allergy, Charité‐Universitaetsmedizin Berlin, Berlin, Germany (Hauttumorcentrum Charité, Klinik für Dermatologie, Venerologie und Allergologie, Charité‐Universitätsmedizin Berlin, Berlin, Deutschland)
| | - Bernhard Lange‐Asschenfeldt
- Skin Cancer Center Charité, Department of Dermatology and Allergy, Charité‐Universitaetsmedizin Berlin, Berlin, Germany (Hauttumorcentrum Charité, Klinik für Dermatologie, Venerologie und Allergologie, Charité‐Universitätsmedizin Berlin, Berlin, Deutschland)
- Department of Dermatology and Venereology, State Hospital Klagenfurt, Klagenfurt am Wörthersee, Austria (Abteilung für Dermatologie und Venerologie, Klinikum Klagenfurt, Klagenfurt am Wörthersee, Österreich)
| |
Collapse
|
29
|
Painsi C, Patscheider M, Inzinger M, Lange-Asschenfeldt B, Quehenberger F, Wolf P. Patient perspectives on treating psoriasis with classic inpatient dithranol therapy: a retrospective patient survey. J Dtsch Dermatol Ges 2016; 13:1156-63. [PMID: 26513076 DOI: 10.1111/ddg.12820] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Evidence of the efficacy of dithranol and patient perspectives on the treatment is scant. PATIENTS AND METHODS Using a telephone interview survey, we collected retrospective data from 63 patients (41 men [65.1 %] and 22 women [34.9 %]) who had been treated with classic inpatient dithranol (CID). PsoRA (www.psoriasisregistry.at) was used to obtain clinical data and treatment responses, which were then correlated with the interview responses. RESULTS Fifty-two (82.5 %) patients achieved a PASI75 and 51 (81 %) a PASI90 response within a median of 12.5 (range: 3 to 25) days. Ten out of twelve (83 %) patients showed a satisfactory response to CID (PASI75 or greater reduction) despite the fact that they had previously failed to adequately respond to methotrexate, oral retinoids, cyclosporine, or ustekinumab. Overall, patients recalled a median recurrence-free interval of four (95 % CI: 3-9) months after responding to CID, which was positively correlated with the patients' recommendation of (p = 0.018) and their overall high satisfaction with the treatment (p = 0.012). CONCLUSIONS Despite the known limitations of CID, this survey indicates that dithranol remains a highly efficacious and valuable treatment option as induction therapy in psoriasis. CID can be effective in patients who have failed to respond to systemic therapy, including traditional agents and biologics.
Collapse
Affiliation(s)
- Clemens Painsi
- Department of Dermatology, Medical University of Graz, Graz, Austria.,Department of Dermatology, State Hospital Klagenfurt, Klagenfurt, Austria
| | | | - Martin Inzinger
- Department of Dermatology, Medical University of Graz, Graz, Austria.,Department of Internal Medicine, Division of Rheumatology and Immunology, Medical University of Graz, Graz, Austria
| | | | - Franz Quehenberger
- Institute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria
| | - Peter Wolf
- Department of Dermatology, Medical University of Graz, Graz, Austria
| |
Collapse
|
30
|
Painsi C, Huegel R, Lange-Asschenfeldt B. Herpes zoster beim Säugling ohne postnatale Varizelleninfektion. J Dtsch Dermatol Ges 2016. [DOI: 10.1111/ddg.12860_g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Clemens Painsi
- Abteilung für Dermatologie und Venerologie; Klinikum Klagenfurt am Wörthersee; Klagenfurt am Wörthersee Österreich
| | - Rainer Huegel
- Abteilung für Dermatologie und Venerologie; Klinikum Klagenfurt am Wörthersee; Klagenfurt am Wörthersee Österreich
| | - Bernhard Lange-Asschenfeldt
- Abteilung für Dermatologie und Venerologie; Klinikum Klagenfurt am Wörthersee; Klagenfurt am Wörthersee Österreich
| |
Collapse
|
31
|
Painsi C, Huegel R, Lange-Asschenfeldt B. Herpes zoster in an infant without postnatal varicella infection. J Dtsch Dermatol Ges 2016; 14:429-30. [DOI: 10.1111/ddg.12860] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Clemens Painsi
- Department of Dermatology and Venereology; Hospital Klagenfurth am Wörthersee; Klagenfurth am Wörthersee Austria
| | - Rainer Huegel
- Department of Dermatology and Venereology; Hospital Klagenfurth am Wörthersee; Klagenfurth am Wörthersee Austria
| | - Bernhard Lange-Asschenfeldt
- Department of Dermatology and Venereology; Hospital Klagenfurth am Wörthersee; Klagenfurth am Wörthersee Austria
| |
Collapse
|
32
|
Inzinger M, Wippel-Slupetzky K, Weger W, Richter L, Mlynek A, Fleischander B, Scheurecker C, Sandor N, Mairhofer D, Sator PG, Moser-Oberthaler S, Häring N, Viznerova P, Painsi C, Tanew A, Ponholzer P, Tatarski R, Brenner W, Stingl G, Salmhofer W, Rappersberger K, Klein G, Saxinger W, Auböck J, Kölli C, Trautinger F, Steiner A, Ratzinger G, Strohal R, Riedl E, Lange-Asschenfeldt B, Pehamberger H, Volc-Platzer B, Selhofer S, Legat FJ, Müllegger R, Reider N, Schmuth M, Hintner H, Hofer A, Gruber-Wackernagel A, Aberer W, Quehenberger F, Wolf P. Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria. Acta Derm Venereol 2016; 96:207-12. [PMID: 26271044 DOI: 10.2340/00015555-2214] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
This retrospective multicentre analysis from the Psoriasis Registry Austria (PsoRA) was conducted to determine drug effectiveness and survival of anti-tumour necrosis factor alpha (anti-TNF-α) agents in patients with moderate-to-severe chronic plaque psoriasis over a 9-year period. Data on 1,019 treatment cycles with adalimumab (n = 460), etanercept (n = 501), and/or infliximab (n = 58) administered to 827 patients (272 women, 555 men) were available for analysis. Compared with etanercept, adalimumab and infliximab showed superior short-term effectiveness. Intention-to-treat-calculated median drug survivals for adalimumab (1,264 days) and etanercept (1,438 days) were similar to each other (p = 0.74), but significantly superior to that of infliximab (477 days) (p = 7.0e-07 vs. adalimumab and p=2.2e-07 vs. etanercept, respectively). Their drug survival rates at 36 months were 51.6%, 56.0%, and 22.6%, respectively. Survival rates correlated significantly with effectiveness for adalimumab and etanercept, but not for infliximab.
Collapse
Affiliation(s)
- Martin Inzinger
- Department of Dermatology, Medical University of Graz, Auenbruggerplatz 8, AT-8036 Graz, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Painsi C, Tarmann R, Würtz FG, Malle P, Wolf P, Hügel R, Lange-Asschenfeldt B. Multiple miliare kutane Osteome am Capillitium. J Dtsch Dermatol Ges 2015. [DOI: 10.1111/ddg.130_12836] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Clemens Painsi
- Abteilung für Dermatologie und Venerologie; Klinikum Klagenfurt am Wörthersee; Österreich
| | - Rebekka Tarmann
- Abteilung für Pathologie, Klinikum Klagenfurt am Wörthersee; Österreich
| | - Franz Georg Würtz
- Abteilung für Pathologie, Klinikum Klagenfurt am Wörthersee; Österreich
| | - Philipp Malle
- Abteilung für Nuklearmedizin und Endokrinologie, Klinikum Klagenfurt am Wörthersee; Österreich
| | - Peter Wolf
- Abteilung für Dermatologie und Venerologie; Medizinische Universität Graz; Österreich
| | - Rainer Hügel
- Abteilung für Dermatologie und Venerologie; Klinikum Klagenfurt am Wörthersee; Österreich
| | - Bernhard Lange-Asschenfeldt
- Abteilung für Dermatologie und Venerologie; Klinikum Klagenfurt am Wörthersee; Österreich
- Klinik für Dermatologie, Venerologie and Allergologie; Charité- Universitätsmedizin Berlin; Berlin Deutschland
| |
Collapse
|
34
|
Painsi C, Patscheider M, Inzinger M, Lange-Asschenfeldt B, Quehenberger F, Wolf P. Die Behandlung der Psoriasis mit klassischer, stationärer Dithranol-Therapie: eine retrospektive Patientenbefragung. J Dtsch Dermatol Ges 2015. [DOI: 10.1111/ddg.70_12820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Clemens Painsi
- Universitätsklinik für Dermatologie und Venerologie; Medizinische Universität Graz; Graz Österreich
- Abteilung für Dermatologie und Venerologie; Klinikum Klagenfurt; Klagenfurt Österreich
| | - Michael Patscheider
- Abteilung für Dermatologie und Venerologie; Klinikum Klagenfurt; Klagenfurt Österreich
| | - Martin Inzinger
- Universitätsklinik für Dermatologie und Venerologie; Medizinische Universität Graz; Graz Österreich
- Universitätsklinik für Innere Medizin; Klinische Abteilung für Rheumatologie und Immunologie; Medizinische Universität Graz; Graz Österreich
| | | | - Franz Quehenberger
- Institut für Medizinische Informatik; Statistik und Dokumentation; Medizinische Universität Graz; Graz Österreich
| | - Peter Wolf
- Universitätsklinik für Dermatologie und Venerologie; Medizinische Universität Graz; Graz Österreich
| |
Collapse
|
35
|
Painsi C, Tarmann R, Georg Würtz F, Malle P, Wolf P, Hügel R, Lange-Asschenfeldt B. Multiple miliary osteoma cutis of the scalp. J Dtsch Dermatol Ges 2015; 13:1185-7. [PMID: 26513089 DOI: 10.1111/ddg.12836] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Clemens Painsi
- Department of Pathology, Klagenfurt am Wörthersee Hospital, Klagenfurt, Austria
| | - Rebekka Tarmann
- Department of Dermatology and Venereology, Klagenfurt am Wörthersee Hospital, Klagenfurt, Austria
| | - Franz Georg Würtz
- Department of Dermatology and Venereology, Klagenfurt am Wörthersee Hospital, Klagenfurt, Austria
| | - Philipp Malle
- Department of Nuclear Medicine and Endocrinology, Klagenfurt am Wörthersee Hospital, Klagenfurt, Austria
| | - Peter Wolf
- Department of Dermatology and Venereology, Medical University Graz, Graz, Austria
| | - Rainer Hügel
- Department of Pathology, Klagenfurt am Wörthersee Hospital, Klagenfurt, Austria
| | - Bernhard Lange-Asschenfeldt
- Department of Pathology, Klagenfurt am Wörthersee Hospital, Klagenfurt, Austria.,Department of Dermatology, Venereology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
36
|
Painsi C, Patscheider M, Inzinger M, Huegel R, Lange-Asschenfeldt B, Quehenberger F, Wolf P. Psoriasis Area and Severity Index 75 rate of classical inpatient dithranol therapy under daily life conditions. Br J Dermatol 2015; 173:815-7. [DOI: 10.1111/bjd.13744] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- C. Painsi
- Department of Dermatology; State Hospital Klagenfurt; Klagenfurt Austria
- Research Unit for Photodermatology; Department of Dermatology; Medical University of Graz; Auenbrugger Platz 8 A-8036 Graz Austria
| | - M. Patscheider
- Department of Dermatology; State Hospital Klagenfurt; Klagenfurt Austria
| | - M. Inzinger
- Research Unit for Photodermatology; Department of Dermatology; Medical University of Graz; Auenbrugger Platz 8 A-8036 Graz Austria
| | - R. Huegel
- Department of Dermatology; State Hospital Klagenfurt; Klagenfurt Austria
| | - B. Lange-Asschenfeldt
- Department of Dermatology; State Hospital Klagenfurt; Klagenfurt Austria
- Department of Dermatology, Venereology and Allergology; Charité, Universitätsmedizin Berlin; Berlin Germany
| | - F. Quehenberger
- Institute for Medical Informatics, Statistics and Documentation; Medical University of Graz; Graz Austria
| | - P. Wolf
- Research Unit for Photodermatology; Department of Dermatology; Medical University of Graz; Auenbrugger Platz 8 A-8036 Graz Austria
| |
Collapse
|
37
|
Ulrich C, Kluschke F, Patzelt A, Vandersee S, Czaika VA, Richter H, Bob A, Hutten JV, Painsi C, Hüge R, Kramer A, Assadian O, Lademann J, Lange-Asschenfeldt B. Clinical use of cold atmospheric pressure argon plasma in chronic leg ulcers: A pilot study. J Wound Care 2015; 24:196, 198-200, 202-3. [PMID: 25970756 DOI: 10.12968/jowc.2015.24.5.196] [Citation(s) in RCA: 85] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
OBJECTIVE In the age of multiresistant microbes and the increasing lack of efficient antibiotics, conventional antiseptics play a critical role in the prevention and therapy of wound infections. Recent studies have demonstrated the antiseptic effects of cold atmospheric pressure plasma (APP). In this pilot, study we investigate the overall suitability of one of the first APP sources for wound treatment focusing on its potential antimicrobial effects. METHOD The wound closure rate and the bacterial colonisation of the wounds were investigated. Patients suffering from chronic leg ulcers were treated in a clinical controlled monocentric trial with either APP or octenidine (OCT). In patients who presented with more than one ulceration in different locations, one was treated with APP and the other one with OCT. Each group was treated three times a week over a period of two weeks. The antimicrobial efficacy was evaluated immediately after and following two weeks of treatment. RESULTS Wounds treated with OCT showed a significantly higher microbial reduction (64%) compared to wounds treated with APP (47%) immediately after the treatment. Over two weeks of antiseptic treatment the bacterial density was reduced within the OCT group (-35%) compared to a slight increase in bacterial density in the APP-treated group (+12%). Clinically, there were no signs of delayed wound healing observed in either group and both treatments were well tolerated. CONCLUSION The immediate antimicrobial effects of the APP prototype source were almost comparable to OCT without any signs of cytotoxicity. This pilot study is limited by current configurations of the plasma source, where the narrow plasma beam made it difficult to cover larger wound surface areas and in order to avoid untreated areas of the wound bed, smaller wounds were assigned to the APP-treatment group. This limits the significance of AAP-related effects on the wound healing dynamics, as smaller wounds tend to heal faster than larger wounds. However, clinical wound healing studies on a larger scale now seem justifiable. A more advanced plasma source prototype allowing the treatment of larger wounds will address APP's influence on healing dynamics, synergetic treatment with current antiseptics and effects on multiresistant bacteria.
Collapse
Affiliation(s)
- C Ulrich
- Department of Dermatology, Charité - University Medicine Berlin, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Bretterklieber A, Painsi C, Avian A, Wutte N, Aberer E. Impaired quality of life in patients with systemic sclerosis compared to the general population and chronic dermatoses. BMC Res Notes 2014; 7:594. [PMID: 25183055 PMCID: PMC4175285 DOI: 10.1186/1756-0500-7-594] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2014] [Accepted: 07/30/2014] [Indexed: 11/20/2022] Open
Abstract
Background Systemic sclerosis (SSc) is a rare and potentially life threatening autoimmune disorder. The burden of disease compared to other dermatoses is unknown. The purpose of this study was to assess both the quality of life in patients with SSc and the variables that are associated with poor quality of life. Forty-one patients with systemic sclerosis (29 limited, 2 diffuse, 10 undifferentiated forms) were assessed with respect to their health status and compared to published data for the normal population, SSc patients from other studies, and patients with chronic skin diseases. Results For the most part, our SSc patients had better outcomes in all 8 dimensions of the SF-36 than SSc patients from other studies, and poorer scores than the healthy population and those with occupational contact dermatitis, ichthyosis, non-melanoma skin cancer, contact dermatitis, atopic eczema, chronic nail disease, vitiligo, health care workers with work-related disease, and those with other chronic skin diseases, but significantly better scores for mental health than those with nail disease, vitiligo, and health-care workers. Patients with atopic dermatitis, psoriasis and pemphigus had significantly poorer mean scores in social function and mental health than SSc patients. Patients with pemphigus were also significantly impaired in their physical and emotional roles. Patients with systemic lupus erythematosus (SLE) had the significantly poorest mean scores for QoL in all 8 domains except bodily pain and emotional role. Conclusion Besides SLE, SSc is one of the most severe chronic dermatologic diseases in terms of reduced QoL. Since SSc cannot be cured, treatment strategies should include therapeutic interventions such as psychotherapy, social support, physiotherapy, and spiritual care. Their beneficial effects could be studied in future.
Collapse
Affiliation(s)
| | | | | | | | - Elisabeth Aberer
- Department of Dermatology and Venereology, Medical University of Graz, Auenbrugger Platz 8, A-8036 Graz, Austria.
| |
Collapse
|